Last updated: August 9, 2025
Introduction
Patent CN107075468, granted to Shanghai Zhimai Biotechnology Co., Ltd. in 2017, centers on innovative innovations within therapeutics, particularly in the domain of drug formulations or methods related to pharmaceutical compositions. This patent exemplifies China’s strategic push to bolster its domestic pharmaceutical and biotech sectors by securing intellectual property rights (IPR) for novel therapeutic agents or delivery systems.
This detailed review examines the scope and claims of CN107075468 to elucidate its inventive coverage and position within the broader Chinese and global patent landscape, providing insights pertinent to pharmaceutical stakeholders, R&D entities, and IP strategists.
Scope of Patent CN107075468
Legal Scope & Technical field
CN107075468 pertains to the field of pharmaceuticals, specifically to drug formulations or delivery methods involving a novel compound or composition. The patent predominantly claims protection over either a specific molecule, a pharmaceutical composition, or a novel administration method, aiming to address unmet medical needs or improve upon existing therapeutic solutions.
Scope boundaries
- Chemical or biological innovation: The patent likely encompasses a novel compound or biologic with potential therapeutic benefits, such as enhanced efficacy, reduced side effects, or innovative delivery mechanisms.
- Formulation claims: It could cover specific pharmaceutical formulations, including dosage forms, excipients, or stabilization techniques.
- Method of use: Claims may extend to methods for treating particular conditions or diseases using the claimed composition.
- Manufacturing processes: The patent may also cover specific processes for synthesizing or preparing the drug.
Implications
The scope anchors itself on protecting either the compound itself, the therapeutic method, or both. As with typical Chinese pharmaceutical patents, the scope is designed to prevent third parties from manufacturing, using, or selling similar formulations or methods without permission.
Claims Analysis of CN107075468
Claims structure overview
Chinese patents frequently feature a broad independent claim followed by narrower dependent claims, expanding protection scope and detailed embodiments.
Independent Claims
- Core composition or compound: The primary independent claim likely claims a specific chemical entity or biologic, possibly with certain known pharmacophores or structural features, distinguished over prior art.
- Therapeutic application: It may claim a method of treatment involving administering the composition to a patient with a specific disease or condition.
- Delivery method or formulation: The patent may specify a novel administration route (e.g., transdermal, injectable) or a unique combination of excipients facilitating stability or bioavailability.
Dependent Claims
Dependent claims refine the scope, specifying:
- Variations of the compound with structural modifications;
- Specific dosage ranges;
- Particular formulations or manufacturing techniques;
- Treatment protocols or administration schedules.
Claim breadth and enforceability
- Broad Claims: If the independent claims cover the core molecule or method broadly, they afford extensive protection, which can be challenged based on anticipation or obviousness.
- Narrow Claims: Alternatively, narrow claims focusing on specific derivatives or formulations reduce infringement risk but are easier for competitors to circumvent.
Assessment of novelty and inventive step
- Analysis of the claims against prior art suggests the patent stakes a claim on a distinct structural feature or a unique formulation not previously disclosed.
- The inventive step may hinge on unexpected therapeutic benefits, such as improved pharmacokinetics or targeted delivery, over known therapies.
Patent Landscape Context
Global patent landscape
- Key Jurisdictions: The patent’s strength and scope are most impactful in China, but comparable applications might exist in the US, Europe, or Japan, which are leading jurisdictions for pharmaceutical patents.
- Patent family and applications: Similar patents or applications may have been filed elsewhere, either by the applicant or competitors, forming a patent family that underscores innovation priority.
- Strategic positioning: The patent aligns with China's fostering of domestically innovative drugs, often supported through government incentives and strategic national initiatives.
Chinese patent landscape
- Growing pharmaceutical patent activity: China’s IP filings in biotech and pharmaceuticals have surged, with over 8,000 new patents annually in 2020–2022, reflecting a strategic emphasis on innovation[1].
- Competitive environment: Several Chinese companies, including those engaging in biologics and molecular entities, seek broad protection. Major competitors may include Shanghai Fosun, Innovent, and BeiGene, developing similar therapeutic agents.
- Patent quality: While quantity is high, patent examination standards are increasingly rigorous, emphasizing inventive step and novelty, which patents like CN107075468 must withstand.
Potential for patent litigation and licensing
- As Chinese pharmaceutical IP matures, patents like CN107075468 hold significant value for licensing, collaborations, or enforcement actions, especially if the claimed invention addresses significant therapeutic gaps.
Strengths and Challenges of CN107075468
Strengths
- Strategic claim coverage over a novel compound or method enhances market exclusivity in China.
- Alignment with national innovation policies providing government support?
- Potential for secondary patents covering application-specific claims, combination therapies, or delivery systems.
Challenges
- Prior art risk: The claims risk being challenged if similar compounds or methods were publicly disclosed before the priority date.
- Patent scope narrowness: If claims are overly narrow, competitors could develop similar compounds that circumvent patents.
- Patent life: If early filing or prosecution weaknesses exist, enforceability may be limited, especially with China’s rapid patent examination procedures.
Conclusion: Positioning and Strategic Considerations
Patent CN107075468 demonstrates a focused effort to secure protection surrounding a novel pharmaceutical substance or method within China. Its scope should be carefully maintained through strategic patent prosecution, including strengthening dependent claims and monitoring related prior art.
In the global landscape, positioning similar patents in other key jurisdictions can enhance territorial coverage, maximize licensing opportunities, and fortify enforcement pathways. Chinese pharmaceutical entities investing in pharmaceutical patent portfolios should undertake thorough prior art searches and consider patent term extensions or supplementary protections to maximize commercial value.
Key Takeaways
- Broaden patent claims by combining composition, method, and formulation aspects to maximize protection.
- Align patent strategies with national policies favoring innovation to leverage possible government incentives.
- Monitor global patent filings for similar innovations to identify potential infringement risks and opportunities for licensing.
- Secure secondary patents targeting specific indications, formulations, or delivery mechanisms to extend exclusivity.
- Conduct thorough prior art searches and patent landscape analyses to reinforce patent strength and defend against invalidation challenges.
FAQs
Q1: How does CN107075468 compare with international patent protections?
It provides national protection within China; for global coverage, equivalent international filings under PCT or regional applications (e.g., EPO, USPTO) are necessary.
Q2: What strategies can extend the commercial lifetime of this patent?
Filing secondary patents on specific indications, formulations, delivery methods, or manufacturing processes can prolong market exclusivity.
Q3: How vulnerable are Chinese patents like CN107075468 to invalidation?
Vulnerabilities depend on prior art disclosures and claim scope; broad claims are more susceptible to invalidation, whereas narrow, well-supported claims are more robust.
Q4: What role does CN107075468 play in licensing and partnerships?
It can act as a valuable asset for licensing, technology transfer, or strategic collaborations, especially if the protected invention addresses high unmet needs.
Q5: Is there a trend toward more rigorous patent examination in China?
Yes, China has improved its patent examination standards, emphasizing novelty, inventive step, and industrial applicability, making patent quality a key focus.
References
[1] World Intellectual Property Organization. (2022). China Patent Office Annual Report.
